Chair for Biological Imaging, Technical University of Munich, Helmholtz Zentrum, Muenchen, Germany,Institute for Biological and Medical Imaging, Helmholtz Zentrum, Muenchen, Germany;
Department of Pathology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Chair for Biological Imaging, Technical University of Munich, Helmholtz Zentrum, Muenchen, Germany,Institute for Biological and Medical Imaging, Helmholtz Zentrum, Muenchen, Germany;
Chair for Biological Imaging, Technical University of Munich, Helmholtz Zentrum, Muenchen, Germany,Institute for Biological and Medical Imaging, Helmholtz Zentrum, Muenchen, Germany;
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands;
Department of Radiology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Department of Pathology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands,Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, the Netherlands;
Research Unit Analytical Pathology, Helmholtz Zentrum, Muenchen, Germany;
Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands;
Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands;
Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, the Netherlands;
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands;
Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, the Netherlands;
Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, the Netherlands;
Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands;
Department of Pathology, University of Groningen, University Medical Center Groningen, the Netherlands;
Department of Gastroenterology, University of Groningen, University Medical Center Groningen, the Netherlands;
Chair for Biological Imaging, Technical University of Munich, Helmholtz Zentrum, Muenchen, Germany,Institute for Biological and Medical Imaging, Helmholtz Zentrum, Muenchen, Germany;
Department of Biology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Department of Surgery, Utrecht University, University Medical Center Utrecht, the Netherlands;
Department of Radiology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Department of Medical Oncology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Chair for Biological Imaging, Technical University of Munich, Helmholtz Zentrum, Muenchen, Germany,Institute for Biological and Medical Imaging, Helmholtz Zentrum, Muenchen, Germany;
Department of Pathology, Utrecht University, University Medical Center Utrecht, the Netherlands;
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands;
Research Unit Analytical Pathology, Helmholtz Zentrum, Muenchen, Germany;
Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands,Department of Nuclear Medicine and Molecular Imaging and Intensive Care, University of Groningen, University Medical Center Groningen, the Netherlands;
Chair for Biological Imaging, Technical University of Munich, Helmholtz Zentrum, Muenchen, Germany,Institute for Biological and Medical Imaging, Helmholtz Zentrum, Muenchen, Germany;
Imaging systems; Medical and biological imaging; Clinical applications;
机译：荧光标记贝伐单抗在人乳腺癌中的阈值分析及生物分布
机译：HER2阴性转移性乳腺癌（IMELDA）患者初始一线贝伐单抗和多西他赛治疗后维持卡培他滨和贝伐单抗与单独使用贝伐单抗的比较：一项随机，开放标签的3期临床研究
机译：贝伐单抗联合紫杉醇与贝伐单抗联合卡培他滨作为HER2阴性转移性乳腺癌（TURANDOT）的一线治疗：一项随机，开放标签，非劣效性的3期试验的主要终点结果
机译：在人乳腺癌中荧光标记的贝伐单抗 - 定义分类阈值
机译：妊娠早期乳房组织的特征有助于确定人工流产对乳腺癌风险的影响
机译：根据不同亮度阈值定义的乳房X线密度预测间隔和筛查的乳腺癌
机译：荧光贝伐单抗-IRDye800CW微剂量在原发性乳腺癌患者中的肿瘤特异性摄取：I期可行性研究
